Bio-Rad Laboratories, Inc
Bio-Rad Laboratories is a U.S.-based multinational that develops, manufactures, and sells tools used in life science research and clinical diagnostics. Its portfolio spans instruments, systems, reagents, consumables, and related services that help customers separate, identify, analyze, and purify biological and chemical materials. The company operates through two reportable segments, Life Science and Clinical Diagnostics, with the diagnostics business contributing the larger share of sales. Bio-Rad sells more than 12,000 products globally and relies on recurring demand from laboratories that need standardized reagents and test workflows.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueInstrumentation and platforms used in biological research, sample preparation, separation, and analysis.
Recurring-use reagents, kits, and consumables sold to research and industrial laboratories.
Medical devices and laboratory systems used in clinical testing and diagnostic workflows.
Test reagents and consumables used with clinical platforms and routine laboratory testing.
Customers
Bio-Rad sells to a broad mix of scientific research, healthcare, education, and government customers worldwide. In life science, the main buyers are university and research institutions, biotechnology and pharmaceutical companies, and industrial labs in chemical and food applications that need standardized tools for experiments and analysis. In clinical diagnostics, customers include hospital, public health, and commercial laboratories, as well as diagnostic manufacturers that use Bio-Rad products in testing workflows. Demand is influenced by research funding, government grants, and reimbursement conditions, which makes end-market funding and healthcare policy important to purchasing behavior.
Buy life science instruments, reagents, and consumables for academic research and standardized experimental workflows.
Buy research tools and analytical products for discovery, development, and quality control activities.
Buy clinical diagnostics systems, assays, and consumables for routine patient testing and lab operations.
Buy components and enabling technologies used in the design and production of diagnostic tests.
Buy analytical products for chemical and food testing, separation, and purification applications.
Strategy
Bio-Rad’s strategy centers on maintaining a broad, differentiated portfolio across life science and clinical diagnostics while supporting customers with direct sales, technical service, and local distribution. The company emphasizes products that perform on technical specifications and customer support, which is important in markets where switching costs and workflow reliability matter. It also continues to invest in research and development, manufacturing capacity, information technology, and selective acquisitions, using operating cash flow, short-term investments, and its revolving credit facility to preserve flexibility. Because much of the business is recurring and global, the company’s strategy also depends on sustaining product quality, regulatory compliance, and international reach.
New instruments, assays, and consumables are needed to defend share in highly competitive markets.
Customers value application support and workflow reliability, which helps Bio-Rad compete against larger peers.
The company needs funding for manufacturing, distribution, IT, and acquisitions while managing global cash flows.
International markets are the majority of sales and expose the company to currency and compliance risk.
Geography
Bio-Rad operates globally through subsidiaries in more than 36 countries outside the United States, supported by direct sales teams and local distributors. In 2025, about 40-41% of consolidated sales came from the United States and about 59-60% from international markets, with Europe the largest international region. The company manufactures in a small number of locations and ships products to local distribution facilities around the world, so supply chain efficiency and cross-border logistics matter to service levels. Foreign exchange is an important factor because international sales and costs are denominated in multiple local currencies, including the euro, Swiss franc, Japanese yen, Chinese yuan, and British sterling.
Risks
Bio-Rad faces meaningful exposure to international regulatory, legal, and operating risks because it sells and manufactures across many jurisdictions. Its clinical diagnostics products are subject to FDA and foreign medical-device regulation, so delays in clearance, approval, or changes in rules can interrupt revenue generation and customer adoption. The company also depends on government funding and reimbursement in several end markets, which makes demand vulnerable to budget pressure and policy changes. In addition, competition is intense across both segments, and quality or product-liability issues could damage customer trust in complex instruments, reagents, and consumables.
- Dependence on government funding and reimbursementImpact: HighLikelihood: High
Research customers rely on grants and clinical customers depend on reimbursement, so budget pressure can reduce demand.
Exposure: Life Science and Clinical Diagnostics
- Regulatory approval and clearance risk for clinical diagnosticsImpact: HighLikelihood: Medium
Clinical products are subject to FDA and foreign medical-device oversight, and delays or adverse rulings can prevent or slow commercialization.
Exposure: Clinical Diagnostics segment
- Product quality and liability issuesImpact: HighLikelihood: Medium
Complex instruments, reagents, and consumables can fail or require remediation, which can hurt reputation and profitability.
Exposure: Global product portfolio
- Competitive pressure in fragmented lab tools marketsImpact: MediumLikelihood: High
Bio-Rad competes with large, well-capitalized peers across multiple product lines, limiting pricing power.
Exposure: Both segments
- Foreign exchange volatilityImpact: MediumLikelihood: Medium
A majority of sales are international and denominated in local currencies, creating translation and margin effects.
Exposure
Accounting
Judgemental itemsContracts may include instruments, reagents, services, licenses, and rentals, requiring allocation across distinct obligations.
Impact: Affects timing and mix of reported revenue
European summer vacation patterns can reduce third-quarter sales and operating income.
Impact: Can distort quarter-to-quarter trend analysis
Reporting unit valuations rely on forecast cash flows and discount rates, which are sensitive to assumptions.
Impact: Could create non-cash charges if business outlook weakens
Management must estimate the resolution of tax matters across jurisdictions.
Impact: Can materially change tax expense and net income
Unrealized gains and losses can affect earnings outside core operations.
Impact: Adds volatility to reported results
Similar listed companies
Publicly listed companies with a comparable business focus.
Biomerica, Inc
BMRA · In Vitro & In Vivo Diagnostic Substances
BIO-TECHNE Corp
TECH · Biological Products, (No Diagnostic Substances)
Bio-Techne Corp develops, manufactures, and sells life science reagents, instruments, and services used in research, diagnostics, and bioprocessing.
Harvard Bioscience, Inc
HBIO · Laboratory Analytical Instruments
Harvard Bioscience designs, manufactures, and sells life-science research tools used in drug discovery, translational medicine, and preclinical testing.
Standard BioTools Inc
LAB · Pharmaceutical Preparations
Quanterix Corp
QTRX · Laboratory Analytical Instruments
Quanterix Corp develops and commercializes ultra-sensitive life science instruments, assay kits, and related services used to measure proteins and biomarkers in biological samples.
Danaher Corporation
DHR · Industrial Instruments For Measurement, Display, and Control
Danaher is a U.S.-based science and technology company organized around biotechnology, life sciences, and diagnostics.
Last updated: 24/09/2026